U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482423) titled 'XVIE to Treat Androgenetic Alopecia (AGA)' on March 12.
Brief Summary: This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss). XVIE contains growth factors and extracellular vesicles that may stimulate hair follicle activity. Thirty participants will be randomly assigned to receive either XVIE or a saline placebo injected into the scalp in two treatment sessions, 90 days apart. Neither participants nor study staff will know which treatment is being given. Participants will be follo...